Are vaccines making a comeback in non-small-cell lung cancer?

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1402-1403

  Nemunaitis, John J ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EP 2101; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GV 1001; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; L 523S; L BLP 25; MELANOMA ANTIGEN 3; PLATINUM DERIVATIVE; PROTEIN B7.1; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYTOKINE; L BLP25; L-BLP25; LIPOSOME; MAGEA3 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ACTIVE IMMUNIZATION; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METHODOLOGY; NOTE; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; IMMUNOTHERAPY, ACTIVE; LIPOSOMES; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41149131700     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2843     Document Type: Editorial

References (22)

1. Alexandroff AB, Jackson AM, O'Donnell MA, et al: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689-1694, 1999
2. Coppin C, Porzsolt F, Awa A, et al: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3:CD001425, 2005
3. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
4. Kaufman HL, Wang W, Manola J, et al: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22:2122-2132, 2004
5. Kwak LW: Translational development of active immunotherapy for hematologic malignancies. Semin Oncol 30:17-22, 2003
6. Quan WD, Dean Jr GE, Spears L, et al: Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 15:2103-2110, 1997
7. Neninger Vinageras EN, de la Torre A, Osorio Rodríguez M, et al: Phase II randomized controlled trial of epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26:1452-1458, 2008
8. Woo EY, Yeh H, Chu CS, et al: Cutting edge: Regulatory T-cells from lung cancer patients directly inhibit autologous T-cell proliferation. J Immunol 168:4272-4276, 2002
9. Dohadwala M, Luo J, Zhu L, et al: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276:20809-20812, 2001
10. Neuner A, Schindel M, Wildenberg U, et al: Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 101:287-292, 2002
11. Fontana A, Frei K, Bodmer S, et al: Transforming growth factor-beta inhibits the generation of cytotoxic T-cells in virus-infected mice. J Immunol 143:3230-3234, 1989
12. Rook AH, Kehrl JH, Wakefield LM, et al: Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916-3920, 1986
13. Tsunawaki S, Sporn M, Ding A, et al: Deactivation of macrophages by transforming growth factor-beta. Nature 334:260-262, 1988
14. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al: Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24:4721-4730, 2006
15. Palmer M, Parker J, Modi S, et al: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3:49-58, 2001
16. Butts C, Murray N, Maksymiuk A, et al: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674-6681, 2005
17. Van den Eynde BJ, van der Bruggen P: T-cell defined tumor antigens. Curr Opin Immunol 9:684-693, 1997
18. Fleischhauer K, Fruci D, Van Endert P, et al: Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer 68:622-628, 1996
19. Keogh E, Fikes J, Southwood S, et al: Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167:787-796, 2001
20. Russo V, Tanzarella S, Dalerba P, et al: Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T-cell response. Proc Natl Acad Sci U S A 97:2185-2190, 2000
21. Halmos BH: Lung Cancer II. ASCO Annual Meeting Summaries. Alexandria, VA, ASCO, 2006, pp 156-160
22. Nemunaitis J, Nemunaitis J: A review of vaccine clinical trials for non-small cell lung cancer. Expert Opin Biol Ther 7:89-102, 2007